Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2024-04-18 Annual Report
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
2023 Annual Report
Annual Report Classification · 100% confidence The document is titled '2023 Annual Report' and contains detailed sections typical of a full annual report, including Chairman's Statement, Management Discussion and Analysis, Corporate Governance Report, Environmental, Social and Governance Report, Report of the Directors, Independent Auditor's Report, and comprehensive financial statements such as Consolidated Statement of Profit or Loss, Financial Position, Changes in Equity, Cash Flow Statement, and Notes to the Financial Statements. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement. The content covers the full fiscal year ended 31 December 2023, with detailed financial and operational data, consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-18 English
UNAUDITED OPERATING RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2024
Earnings Release Classification · 95% confidence The document is an announcement of unaudited operating results for the three months ended 31 March 2024. It explicitly states that the financial information is unaudited and based on management accounts, and it cautions that this information is not the audited financial results. The document is relatively short (4618 characters) and serves as an initial disclosure of quarterly financial performance highlights rather than a comprehensive financial report. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Interim/Quarterly Report (IR) because it lacks substantive financial statements or detailed analysis, and it is not an Annual Report (10-K) or any other detailed report. Therefore, the correct classification is Earnings Release (ER). Q1 2024
2024-04-16 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of SSY Group Limited regarding recent approvals from the National Medical Products Administration of China for product development related to generic drugs. It is an update on business developments rather than a financial report or regulatory filing. The document is relatively short (2072 characters) and does not contain financial statements, audit information, or detailed management discussion. It is not an announcement of voting results, capital changes, or legal proceedings. The content fits best under a general regulatory announcement category as it informs shareholders and investors about business progress without financial data or formal report structure.
2024-04-08 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors about recent approvals for drug production and registration from the National Medical Products Administration of China. It provides updates on product development and regulatory approvals but does not contain financial statements, detailed financial analysis, or comprehensive report content. The document is relatively short (2477 characters) and serves to inform shareholders and investors about business developments rather than presenting a formal report or financial results. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other specific categories.
2024-04-03 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities for SSY Group Limited, including authorized share capital, issued shares, share options, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital changes and confirmations rather than financial performance, management changes, or earnings. It is a regulatory compliance filing specific to share capital movements and confirmations, not an annual or quarterly report, earnings release, or management discussion. The document is comprehensive and contains substantive data on share capital movements, so it is not a brief announcement or certification. This type of document aligns with the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-04-02 English
Final Dividend for the year ended 31 December 2023
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Final Dividend for the year ended 31 December 2023' and contains detailed information about the dividend amount, payment dates, record dates, and related shareholder information. It is an announcement specifically about the dividend amount and payment details rather than a full financial report or other type of filing. The document length is 3253 characters, which is relatively short and focused solely on dividend information. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2024-03-27 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.